eligible ages (years): 18.0-999.0,  All  Bleeding Peptic Ulcer Arterial Embolization Actively bleeding peptic ulcers (Forrest I), NBVV or Forrest IIa ulcer Successful endoscopic hemostasis by combination treatment of injected epinephrine followed by either 3.2mm heat probe 30J (4 continuous pulses) or hemo-clipping (at least 2 clips) And one of the followings Spurting hemorrhage during endoscopy Ulcer >= 2 cm is determined by an opened biopsy forceps Hb on admission of < 9 g/dl; or Hypotension prior to endoscopy defined by SBP of <90 mmHg AND HR of >110 bmp


A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

eligible ages (years): 18.0-999.0,  All  Peptic Ulcer Bleeding Age ≥ 18 Confirmed ulcer bleeding with Forrest Ia, Ib, IIa, IIb Endoscopic hemostasis achieved Informed consent obtained  No consent Forrest II c, III (clear ulcer base/flat spot and no active bleeding, i.e., minimal risk for rebleeding) Unsuccessful endoscopic treatment (i.e., injection and/or thermal coagulation for the initial bleeding) or severe bleeding that immediate surgery is indicated Moribund patients in whom active treatment of any form is not considered Polytrauma, severe injury, unconsciousness, burns, or need for continuous artificial ventilation Upper GI malignancy or disseminated malignant disease Esophageal varices A Mallory-Weiss lesion Phenytoin or theophylline treatment Uses of PPI or H2RAs within 3 days of admission, including uses at Emergency Department N.B. Usage of aspirin or NSAID is not an


eligible ages (years): 18.0-999.0,  All  Upper Gastrointestinal Bleeding Established diagnosis of acute upper gastrointestinal bleeding, confirmed by presence of hematemesis/ coffee ground vomiting, melena, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract Written informed consent provided prior the start of participation in the study  Subjects who are unwilling or unable to provide informed consent


eligible ages (years): 1.0-14.0,  All  Gastroenteritis All acute gastroenteritis patient between 1-14 years presenting to PEC Al Saad with diarrhea, persistent vomiting , fail oral rehydration and admitted to the observation unit for intravenous hydration will be eligible for the study  Previous abdominal surgery Suspicion of surgical abdominal Bile stained vomitus History of hepatic and renal illnesses In-born error of metabolism Children with shock or impending shock Sever dehydration Previous hypersensitivity or abnormal reaction to metoclopramide or ondansetron Antiemetic treatment within 48 hours prior to presentation Seizure disorder


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer A history of H. pylori-negative idiopathic peptic ulcers, defined as No exposure to aspirin, NSAIDs or drugs of unknown nature including traditional Chinese medicine within the 4 weeks before hospitalization Biopsies taken during endoscopy must be negative for both the urease test and histology for H. pylori in the absence of acid suppressive therapy; and No other causes of ulceration identified Endoscopically confirmed ulcer healing Age >18 years old Informed consent  Concomitant steroid or anticoagulant Concomitant use of NSAIDs, aspirin or COX2 inhibitors Previous gastric surgery Requirement of maintenance PPI (e.g. reflux oesophagitis) Advanced comorbidity (defined as ASA 4 or above) or active malignancy Subjects who are pregnant or lactating, or is intending to become pregnant before, during, or within 1 month after participating in this study Subjects who have known hypersensitivity or allergies to any component of lansoprazole or famotidine Subject who has current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition


eligible ages (years): 18.0-999.0,  All  Peptic Ulcers Age ≥ 18 Confirmed ulcer bleeding with Forrest Ia, Ib, IIa Endoscopic hemostasis achieved by combined endoscopic hemostasis Informed consent obtained  No consent Unsuccessful endoscopic treatment Upper GI malignancy History of subtotal gastrectomy Bleeding tendency, platelet count < 80x109/L, prothrombin time INR >1.5 Myocardial infarction or cerebrovascular accident within one week Ulcer bleeding because of mechanical factors (such as, induction of NG tube) Malignancy or other advanced disease with a life expectancy of < 6 months IV PPI > 40mg within 24hrs before enrollment Decompensated liver cirrhosis


eligible ages (years): 18.0-999.0,  All  Re-bleeding in NVUGIB Adult patients (>=18yrs) admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia Evidence that an upper GI endoscopy was performed  GI bleeding not from


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer aspirin users who have a peptic ulcer confirmed by endoscopy  serious medical illness (including cardiovascular events within 6 months before endoscopy) acute gastrointestinal bleeding a history of gastric or duodenal surgery allergic to the study drugs require long-term treatment with non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, or anticoagulant agents pregnancy


eligible ages (years): 18.0-999.0,  All  Melena Hematemesis Peptic Ulcer Hemorrhage Variceal Hemorrhage Patients greater than 18 Patients presenting with actual or reported hematemesis or coffee ground emesis or melena  Refusal to participate Patient is hemodynamically unstable People with dysphagia or another swallowing disorder Pacemaker Known or suspected gastrointestinal obstruction, stricture or fistula Prisoners Patient lacks the ability to give informed consent High suspicion of pregnancy


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer Bleeding A history of documented peptic ulcer bleeding (self-reported history without confirmation by the clinician is not acceptable) Negative tests for H. pylori or successful eradication of H. pylori based on urease test and histology Expected regular use of ASA for the duration of the trial Age ≥ 18 Written informed consent obtained  A history of gastric or duodenal surgery other than patch repair Severe erosive esophagitis (LA grade C or D) Gastric outlet obstruction Terminal illness Active malignancies


eligible ages (years): 15.0-999.0,  All  Blunt Trauma Penetrating Wound Hemorrhagic Shock Included will be those with Blunt or penetrating injury Age ≥15yrs or weight ≥50kg if age is unknown Prehospital SBP ≤ 90 mmHg  Excluded will be those with Ground level falls Evidence of severe blunt or penetrating head injury with a Glasgow Coma Scale (GCS) ≤ 8 Bilateral paralysis secondary to suspected spinal cord injury Fluid greater than 250ml was given prior to randomization Cardiopulmonary resuscitation (CPR) by Emergency Medicine Service (EMS) prior to randomization Known prisoners Known or suspected pregnancy Drowning or asphyxia due to hanging Burns over a Total Body Surface Area (TBSA) > 20%


eligible ages (years): 18.0-85.0,  All  Postoperative Nausea and Vomiting (PONV) Nausea Adult patients to 85 years of age Scheduled for neurosurgery requiring opening of the cranium and dura at Ohio State University Medical Center and who consent in writing to participate in this study are eligible  Patients will be excluded from this study if they are prisoners pregnant women mentally ill under the age of 18 or over the age of 85 American Society of Anesthesiologist (ASA) classification V alcohol or drug abusers have a cerebral perfusion pressure (CPP) greater than 150 mmHg or less than 50 mmHg


eligible ages (years): 20.0-80.0,  All  Esophageal Cancer cytologically or histologically confirmed esophageal carcinoma age of 20 -80 Karnofsky performance status ≥ 70 no treatments prior to enrollment at least one measurable lesion on CT, MRI or esophageal barium exam normal functions of heart, lung, liver, kidney and bone marrow blood exams qualified for chemotherapy, which included hemoglobulin ≥9 g/dl, neutrophil ≥1.5×109/L and platelet (PLT) ≥100×109/L, creatinine ≤1.5 UNL informed consent signed  prior treatments of chemotherapy or irradiation poor bone marrow, liver and kidney functions, which would make chemotherapy intolerable contraindication for irradiation: complete obstruction of esophagus, deep esophageal ulcer, fistula to mediastinum, or haematemesis participating in other clinical trials pregnancy, breast feeding, or not adopting birth control drug or alcohol addiction, uncontrolled epileptic seizure, or psychotic with no ability of self control coexisted morbidities that investigators believed not suitable for chemoradiation


eligible ages (years): 16.0-60.0,  All  Blood, Injection, Injury Type Phobia Gastrointestinal Ulcer Haemorrhage Adverse Reaction to Epinephrine all adult patients with gastroduodenal ulcer  Patients with non ulcer bleeding Patients with malignancy Patients with bleeding disorders or under coagulation therapy Patients with known allergy to epinephrine


eligible ages (years): 39.0-83.0,  All  Peptic Ulcer Bleeding Hypoalbuminemia Clinical presentations of melena, hematochezia, or hematemesis Gastroscopy confirmed peptic ulcers and major stigmata of recent hemorrhage A Rockall score ≥ 6  Gastric or esophageal, or duodenal tumor bleeding Ulcer due to mechanical factors Warfarin use Failure to establish hemostasis under gastroscopy Hypersensitivity to omeprazole, esomeprazole, albumin or any component of the formulation


eligible ages (years): 18.0-999.0,  All  Trauma Hemorrhagic Shock Age>=18 years Acutely injured SBP<70 mmHg or SBP 71-90 mmHg with heart rate (HR)>108 beats per minute  Visibly or verbally reported pregnant women known prisoners unsalvageable injuries (defined as asystolic or cardiopulmonary resuscitation prior to randomization) known objection to blood products the patient has an opt-out bracelet or, necklace or wallet card a family member present at the scene objects to the patient's enrollment in research


eligible ages (years): 0.0-999.0,  All  Bleeding Peptic Ulcer General practitioners in the Region of Southern Denmark which are linked to Danish General Medical Database for minimum 6 months


eligible ages (years): 40.0-84.0,  All  Peptic Ulcer [Iowa Type (107680.0010)] Patients aged 40-84 years in 1997-2005 ( see study population description)  Patients aged below age 40 and 85 years and above ( see study population description)


eligible ages (years): 18.0-999.0,  All  Acute Abdomen All patients with acute abdomen undergoing abdominal surgery under emergency and presenting on arrival in ICU at least a sign of bad perfusion  Patients with chronic renal failure already receiving dialysis treatment Acute Coronary Syndrome (ACS) <12 months and New York Hearth Classification (NHYA ) class > 3 Patients judged at the admission not subject to resuscitative measures for severity and comorbidity Patients with massive hemorrhage in operative room or in the immediate perioperative with the need for blood transfusions and abundant blood products > 5 units of Erytrocyte Concentrates (EC) Patients scheduled for Orthotopic Liver Transplantation (OLT) Patients younger than 18 years old


eligible ages (years): 18.0-80.0,  All  Gastric Varices Portal Hypertension Patients presented to our hospital with acute gastric variceal bleeding, with or without liver cirrhosis The age of the patients range from 18 to 80 years old  Patients who have contraindications for cyanoacrylate, lipiodol or lauromacrogol therapy Patients who have abnormal portosystemic shunt according to the imaging results Patients who have no previous upper gastrointestinal bleeding history Patients who have multiple endoscopic treatments for esophagogastric varices before


eligible ages (years): 20.0-75.0,  All  Gastric or Duodenal Ulcer Patients with peptic ulcer disease Age: 20-75 years old Patients who submitted informed consent  Peptic ulcer disease with spurting and oozing Shock, hypotension, pregnancy Gastrointestinal malignancy


eligible ages (years): 19.0-85.0,  All  This Study Will Provide Data Comparing Safety of LMWH Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment. Adults, age ≥ 18 years Patients who have signed the study informed consent form prior to initiation of any study-related procedure Acute massive PE patients who require thrombolytic treatment  Patients who have a contraindication to use of anticoagulation and thrombolysis, such as active bleeding, stroke, cranial trauma, or neurologic surgery within the preceding 6 months, current pregnancy, major surgery, or biopsy within the preceding 7 days, major trauma within the preceding 10 days, gastrointestinal bleeding within the preceding 1 months during their admission Patients who received any anticoagulation medication prior to admission to the hospital


eligible ages (years): 18.0-999.0,  All  Chemotherapy-induced Nausea and Vomiting Minimum age of 18 years Histologically proven solid organ cancer Eastern Cooperative Oncology Group Performance status 0-2 More than 3 months for life expectancy Patients scheduled to receive the first line, first cycle (5-FU, Oxaliplatin, Leucovorin) or (5-FU, Irinotecan, Leucovorin) chemotherapy Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital  Patients who have nausea and vomiting caused by other reasons such as CNS metastases or gastrointestinal obstruction Patients who were exposed previously to any chemotherapy except adjuvant FL (5-FU and leucovorin) Patients who take anti-emetic drugs or dopamine antagonist within 72 hours prior to administration of chemotherapy Patients who take other drugs that may affect serum level of biomarkers (ex. steroid, megesterol, hormone replacement therapy, parenteral nutrition)


eligible ages (years): 18.0-80.0,  All  Upper Gastrointestinal Bleeding Adult patients (18-80) who are admitted to the ICU for hematemesis, or coffee ground emesis  Patients younger than 18 yrs old or older than 80 yrs Patients who refuse to consent to be in our study Pregnant patients Prior use of prokinetics in the last 48 hours History of cardiac arrhythmia Allergy to erythromycin or metoclopromide Patients with QT prolongation (query 7)


eligible ages (years): 18.0-50.0,  All  Nausea Vomiting undergoing elective orthognathic surgery age 18-50 year olds signed informed consent  pregnant women past history of oesophageal surgery, oesophageal varices or stricture patients who have received antiemetic medication in the 24 hours before surgery emergency surgery prior history of motion sickness and/or PONV, vertigo or migraine headaches


eligible ages (years): 21.0-999.0,  All  Bleeding Peptic Ulcers Peptic ulcer with high-risk stigmata of recent hemorrhage (Forrest class IA, IB, IIA and IIB)  Patients younger than 21 years of age Refusal to participate in study Contraindicated for endoscopy Pregnant or lactating patients Bleeding secondary to non-peptic ulcer source Patients requiring mechanical ventilation Patients with acute coronary syndrome


eligible ages (years): 18.0-999.0,  All  Gastrointestinal Hemorrhage Adults aged 18 or over years presenting with AUGIB, defined by haematemesis or melaena  Patients with whom the responsible clinician considers there is a need for immediate RBC transfusion prior to obtaining or regardless of the initial Hb result due to severity of bleeding Existing hospital in-patients who develop AUGIB


eligible ages (years): 18.0-999.0,  All  Gastrointestinal Hemorrhage Patients presenting with fresh blood hematemesis, coffee ground emesis, or melena Patients with hematochezia and hypotension (systolic blood pressure < 90 mm Hg) or tachycardia (heart rate > 110 beats per minute)  Identification of a bleeding source within the first 5 minutes of the upper endoscopy or no blood seen in the upper GI tract as these patients do not require additional suctioning Age < 18 No endoscopy was performed Endoscopy previously performed for current episode of UGIB Patients unable to consent and who do not have a substitute decision maker


eligible ages (years): 18.0-70.0,  All  Gastric Ulcer Induced by Anti-platelet Agent Duodenal Ulcer Induced by Anti-platelet Agent Age 18-70 year-old Had cardiovascular disease which needed clopidogrel and aspirin Stable enough for gastroscopy  Gastroscopy revealed peptic ulcer Had contraindication for gastroscopy Not allowed for gastroscopy by cardiologist


eligible ages (years): 20.0-95.0,  All  Peptic Ulcer Hemorrhage Bleeding peptic ulcers with major stigmata of recent hemorrhage All of these major SRH are treated by local injection of diluted epinephrine 1:10000 with or without combined therapy with a heater probe, argon plasma coagulation, band ligation, or hemoclip therapy  Bleeding due to tumor or cancer Bleeding due to the presence of a Dieulafoy lesion Ulcer bleeding due to mechanical factors (i.e., gastrostomy tube induction) Proton pump inhibitors use within one week before enrollment Failure to establish hemostasis under gastroscopy Hypersensitivity to esomeprazole, pantoprazole, or any component of the formulation Previously participated in the study


eligible ages (years): 20.0-999.0,  All  Bleeding Ulcers (i) over 20 years of age and (ii) patients with high-risk peptic ulcer bleeding  (i) the presence of another possible bleeding site (eg, gastroesophageal varix, gastric cancer, reflux esophagitis); (ii) coexistence of actively severe ill diseases (eg, septic shock, stroke, myocardial infarction, surgical abdomen); (iii) treatment with an anticoagulant (eg, warfarin); (iv) pregnancy; (v) the presence of operated stomach or; (vi) refusal to participate in the study


eligible ages (years): 18.0-999.0,  All  Bleeding Peptic Ulcer Patients presented with bleeding peptic ulcers Age > 18 year old Informed consent for the study and OGD  Unable or refuse to give consent Onset more than 7 days Pregnancy


eligible ages (years): 0.0-999.0,  All  Stress Ulcers Stress-related Mucosal Disease (SRMD) The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments. Those whose Glasgow Coma Scale (GCS) ≤10[4] within 24 hours of lesion/admission will be defined as critically ill patients. Three kinds of cases will be included: brain trauma critically ill patients, cerebral haemorrhage critically ill patients or postoperative brain tumour critically ill patients  If participating in any clinical trial, the subject cannot take part in this study. Subjects are ineligible if they have below conditions Those who were likely to swallow blood (for example, those with severe facial trauma or epistaxis Patients with previous total gastrectomy Known upper GI lesions that might bleed (e.g., varices, polyps, tumours, etc) Evidence of active GI bleeding including oesophageal and gastric variceal bleeding, Peptic Ulcer Disease (PUD)


eligible ages (years): 19.0-999.0,  All  Peptic Ulcer Male or female over 19 years of age Accompanied by hypertension, diabetes, ischemic heart disease, arrhythmia, dyslipidemia patients who are required to continuous administration of low-dose aspirin(100mg) Patients who get Modified Lanza Score (MLS) 0 in screening period according to endoscopic findings Patients who have stomach or duodenal ulcer scar in screening period according to endoscopic findings. But, the cases that scars caused by other disorders or endoscopic treatment are excluded Patients who have no digestive symptoms(except for mild physconia, abdominal pain, diarrhea and vomit, nausea-vomiting) in screening period Signature of the written informed consent  Within 4 weeks prior to screening period, patients who continuously take aspirin or NSAIDs Patient who has hypersensitivity to PMK-S005 and aspirin components or is banned to use them Patients who had a abdominal surgery that affect gastrointestinal motility (Except appendectomy and hysterectomy), But, patients who had enterectomy is excluded regardless of the time period Patients who are judged by investigator that they have other upper gastroesophageal disease, active/healing-stage peptic ulcer, digestive malignant tumor or Barrett's esophagus Patients with Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), Ulcerative Colitis, Crohn's disease, Zolinger-Ellison syndrome History of esophagus, liver, pancreas, stomach, colorectal cancer or malignant tumors within 5 years History of malabsorption within 3 months prior to screening period Patients who have been taken drug that affect the validity within 2 weeks before beginning of the clinical test Patient who is needed continuously to take antithrombotic agents , anti coagulant , anti


eligible ages (years): 18.0-999.0,  All  Ulcer Bleeding Age >=18 Informed consent obtained Successful endosopic hemostasis Risk Score >= 5  Age < 18 Pregnancy Incomplete endoscopic haemostasis -


eligible ages (years): 18.0-999.0,  All  Pain, Postoperative Postoperative Nausea and Vomiting Postoperative Hemorrhage Body Weight Changes years and older Surgical indications: Chronic tonsillitis, Snoring, Sleep apnea Surgical procedure: Tonsillectomy with monopolar cautery, hemostasis with monopolar cautery and/or suction cautery. The surgical procedure can also Adenoidectomy with suction cautery  Additional surgical procedures (i.e. UPPP (uvulopalatopharyngoplasty), septoplasty, inferior turbinate reduction) during same surgery Pregnant females Indications: Suspected malignancy History of chronic pain or daily pain medication used for another medical problem History of liver disease Contraindications to preoperative Decadron Contraindications to pain regimen medications (Tylenol, Norco, Percocet, Dilaudid)


eligible ages (years): 18.0-65.0,  All  Oral Glucose Tolerance Body mass index (BMI) of 18.0-30.0 kg/m2 and with no known diseases  systemic infections, psychiatric or metabolic disorders, known food allergies or intolerances related to the products used in the study (e.g. dairy or gluten), ongoing or former drug abuse, high intake of alcohol (defined as a weekly intake of >7 units for women and > 14 units for men), pregnancy or ongoing planning of pregnancy, vegetarianism or veganism, participation in other scientific studies during the study period, and blood donation during or in the month leading up to the study period


eligible ages (years): 18.0-999.0,  All  Overt Upper Gastrointestinal Bleeding Individual aged ≥ 18 years presenting to the emergency department with acute, overt UGIB defined as coffee ground vomiting and/or melena  UGIB with hemodynamic shock (BP<90mmHg and pulse>120 per minutes) requiring urgent endoscopy UGIB with fresh hematemesis requiring urgent endoscopy dysphagia, odynophagia, swallowing disorder, Zencker's diverticulum, suspected bowel obstruction or bowel perforation prior bowel obstruction, gastroparesis or known gastric outlet obstruction, Crohn's disease, past GI tract surgery presence of an electromedical device (pacemaker or internal cardiac defibrillator) altered mental status (e.g., hepatic encephalopathy) that would limit patient ability in swallowing the capsule, pregnancy and/or lactating, allergy to conscious sedation medications, allergy to Maxolon, unwillingness to swallow the capsule, patient expected to undergo Magnetic Resonance Imaging examination within 7 days of ingesting the capsule, patient on medications that may coat the upper GI tract such as antacids or sucralfate, or inability to provide written informed consent Allergy to Maxolon Patients with known Esophageal Varices or Gastric Varices with or without prior bleeding episodes Known upper/ lower GI cancer (eg, cancer of esophagus, stomach, small bowel, colon) or hepatocellular carcinoma or pancreatic cancer


eligible ages (years): 20.0-95.0,  All  Peptic Ulcer Hemorrhage Eligible participants included patients ≥20 years who had undergone gastroscopy for melena, haematochezia, or haematemesis due to bleeding peptic ulcers with major stigmata of recent hemorrhage. The major stigmata of recent haemorrhage were classified as Forrest class Ia, Ib, IIa, and IIb. All of the stigmata are given one or a combination of endoscopic therapies, including local injection of diluted epinephrine 1:10000, bipolar heated probe, argon plasma coagulation, band ligation, or hemoclip therapy. Patients will undergo a follow-up endoscopy about 12 to 16 weeks later to confirm that the ulcer has healed to be less than 0.5 cm; otherwise, patients are not enrolled  Patients are excluded if they had tumor bleeding or ulcer bleeding due to the presence of a Dieulafoy lesion or mechanical factors (e.g, gastrostomy tube induction), comorbid with reflux esophagitis grade C or D, Barrett's esophagus, or marginal ulcer bleeding, hypersensitivity to esomeprazole or any component of the formulation, or had previously participated in the study. Because of concern for patient safety with certain drug-drug interactions, patients who receive anti-platelet therapy, e.g., aspirin, clopidogrel, or others for prophylaxis of established cardiovascular or cerebrovascular diseases will be excluded


eligible ages (years): 19.0-85.0,  All  Hemorrhage, Surgical Hip Replacement, Total Thrombocytopathy patient scheduled for elective hip replacement surgery age between 19-85 years signed informed consent  informed consent not signed traumatic hip fracture anemia (hemoglobin level < 100 g/l) allergy to study drug and/or multiple allergies chronic heart failure with LVEF < 30% shock states coagulopathy thrombocytopenia thrombocytopathy chronic kidney disease with oliguria


eligible ages (years): 18.0-45.0,  All  Anesthesia; Adverse Effect, Spinal and Epidural Hypotension Complications; Cesarean Section The American Society of Anesthesiologists (ASA) Physical Status classification 1 and 2 Pregnant women with singleton pregnancy Gestational age greater than 36 weeks Cesarean delivery under spinal anesthesia  Use of cardiac medication or medication for blood pressure control Cardiovascular disease Multiple gestation Gestation diabetes requiring insulin Refusal to be in study History of chronic opioid use (chronic pain syndrome) Emergent caesarean delivery for maternal and/or fetal distress Preeclampsia Eclampsia Progressive neurologic disease


eligible ages (years): 18.0-65.0,  All  Shock, Hemorrhagic Fractures, Bone Multiple Trauma multitrauma defined as Injury Severity Score (ISS) > 17 dislocated pelvic fracture type B or C according to Tile[10] on emergency department pelvic radiograph hemodynamic instability defined as systolic blood pressure (SBP) <90 mmHg after administration of 4 units of packed red blood cells (PRBC)  monotrauma, or ISS ≤ 17 age > 65 years age < 18 years


A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for  two years of infertility treatment and an ectopic pregnancy at age 26.

eligible ages (years): 18.0-50.0,  All  PMDD PMS Depression The subjects of this study will be women who meet the for MRMD as described in Protocol No. 81-M-0126, 'The Phenomenology and Biophysiology of Menstrually-related Mood and Behavioral Disorders.' In brief, these history within the last two years of at least six months with menstrually-related mood or behavioral disturbances of at least moderate severity--i.e., disturbances that are distinct in appearance and associated with a notable degree of subjective distress symptoms should have a sudden onset and offset age 18-50 not pregnant and in good medical health medication free All patients participating in this protocol will have already participated in Protocol No. 81-M-0126 and will have a prospectively confirmed and predictable relationship between their mood disorder and the premenstrual phase of the menstrual cycle, i.e., a 30% change in severity of symptom self rating scales, relative to the range of the scale employed, during the seven days premenstrually compared with the seven days post-menstrually in two out of three months of study The Schedule for Affective Disorders and Schizophrenia will be administered to all patients prior to study entry. Any patient with a current axis I psychiatric diagnosis will be excluded from participating in this protocol Prior to treatment, a complete physical and neurological examination will have been performed and the following routine laboratory data obtained A. Blood  The following conditions will constitute contraindications to treatment with hormonal therapy and will preclude a subject's participation in this protocol current Axis I psychiatric diagnosis history consistent with endometriosis diagnosis of ill-defined, obscure pelvic lesions, particularly, undiagnosed ovarian enlargement hepatic disease as manifested by abnormal liver function tests history of mammary carcinoma history of pulmonary embolism or phlebothrombosis undiagnosed vaginal bleeding porphyria diabetes mellitus


eligible ages (years): 18.0-55.0,  All  Porphyria ENTRY --Disease Characteristics- Acute porphyria, i.e.: Acute intermittent porphyria Hereditary coproporphyria Variegate porphyria Definite cyclic attacks with severe abdominal pain and other porphyria symptoms during luteal phase of menstrual cycle only Attacks resolve completely within 5 days of onset of menses, i.e., no symptoms between attacks At least 4 to 6 attacks during the 6 months prior to entry More than half of these attacks must meet the following Readily distinguishable from menstrual cramps and premenstrual syndrome Required hospitalization for narcotic analgesics, phenothiazines, hematin, intravenous fluids, or other treatment Luteal attacks not requiring hospitalization must be similar in symptoms and differ only in severity No life-threatening porphyria attacks No cyclic abdominal pain unless caused by porphyria --Prior/Concurrent Therapy- At least 6 months since ovulation suppression --Patient Characteristics- Reproductive: Menstrual cycle 25-35 days for at least 6 months prior to entry Pelvic exam normal within 60 days prior to entry Pap smear normal, i.e., no dysplasia No amenorrhea No other menstrual abnormality No other gynecologic abnormality Negative pregnancy test Medically approved contraception required for 2 months prior to entry and throughout study OR at least 1 menstrual cycle following tubal ligation Other: No allergy to gonadotropin-releasing hormone analogues No clinically significant abnormal laboratory test results No medical contraindication to protocol treatment


eligible ages (years): 18.0-999.0,  All  Amphetamine-Related Disorders years of age. Treatment seeking for meth dependence  Please contact site director for more details


eligible ages (years): 18.0-40.0,  All  Endometrial Bleeding Periodontal Disease Regular menstrual periods for the last 2 cycles Currently not using hormonal contraceptives, including oral contraceptives, patch, ring, or Norplant in 2 months prior to study entry, or Depo-Provera in 12 months prior to study entry Currently not using tetracycline-class antibiotics Normal Pap smear  Pregnancy or breastfeeding within 2 months of study entry Chronic migraine headaches Uncontrolled high blood pressure Untreated sexually transmitted diseases Alcoholism or drug abuse within 12 months of study entry Insulin dependent diabetes Liver, kidney, or gallbladder disease Participation in another clinical trial within 30 days of study entry History of cancer History of blood clots, strokes, or heart disease


eligible ages (years): 18.0-45.0,  All  Endometriosis Female patients with endometriosis-associated pelvic pain  Pregnant or lactating women history or suspicion of hormone dependent tumor therapy resistant endometriosis need for primary surgical treatment any other conditions which forbid the participation


eligible ages (years): 21.0-40.0,  All  Infertility Female partner age 21 up to 40th birthday, at the time of recruitment. Infertility is defined as failure to conceive a recognized pregnancy after one year (or 12 menstrual cycles) of unprotected intercourse Male partner has a normal semen analysis with a sperm concentration of >15 million total motile sperm, >1% normal forms by strict or >5 million total motile sperm on IUI prep Female patient has at least one ovary and at least one ipsilateral patent fallopian tube confirmed by HSG or laparoscopy; pelvic pathology amenable to operative laparoscopy (pelvis restored to functional). The open tube cannot have had a previous ectopic (tubal) pregnancy and the closed tube cannot be a hydrosalpinx (a tube that is blocked at the end and filled with fluid), unless a tubal ligation has been performed at the junction of the uterus and fallopian tube Patients with surgically corrected stages I and II endometriosis will be included Normal uterine cavity demonstrated by HSG, Sonohysterogram (SHG), or hysteroscopy; pathologies of uterine cavity amenable to operative hysteroscopy (cavity restored to normal and demonstrated by post operative study) Anovulatory patients who did not conceive after a minimum of three ovulatory cycles with any medications, not including gonadotropin therapy. Anovulatory patients unable to achieve ovulation at dosages up to 150 mg of clomiphene or standard dosages of other ovulation inducing medications (i.e. bromocriptine). Hypoestrogenic hypothalamic amenorrhea patients will qualify immediately for prior to any gonadotropin therapy Normal ovarian reserve demonstrated in all patients i.e., cycle day 3 FSH/E2 values of <15 mIU/mL and <100 pg/mL, respectively. Normal TSH and prolactin Female body mass index ≤ 38  Previous tubal reconstructive surgery in which the pelvis was not restored to functional Unilateral or bilateral hydrosalpinx (a tube that is blocked at the end and filled with fluid) that has not had a tubal ligation performed at the junction of the uterus and fallopian tubes A laparoscopy that demonstrated pelvic adhesions or endometriosis for which the pelvis could not be restored to normal by surgery or endometriosis was not ablated or excised. All patients with stages III and IV endometriosis One or more prior ectopic pregnancies in which one or both tubes were rendered nonfunctional; two or more ectopic pregnancies, even if tubes are patent Severe male factor (i.e.; semen analysis with a sperm concentration of <15 million total motile sperm, <1% normal forms by strict or <5 million total motile sperm on IUI prep). Couples using donor semen will be excluded Previous treatment with IUI or IVF. Previous treatment of normal ovulation patients with gonadotropins Inadequate ovarian reserve demonstrating FSH >15 mIU/mL or estradiol > 100 pg/mL Patients requiring gamete intrafallopian tube transfer (GIFT), zygote intrafallopian tube transfer (ZIFT), or tubal embryo transfer (TET) Female body mass index > 38


eligible ages (years): 25.0-50.0,  All  Leiomyoma Female gender-to evaluate effects in the target population for clinical trials History of uterine leiomyoma causing symptoms of bleeding, pressure, or pain, as defined by the American College of Obstetrics and Gynecology (ACOG) practice bulletin Excessive uterine bleeding will be evidenced by either of the following-profuse bleeding with flooding or clots or repetitive periods lasting for more than 8 days; or anemia due to acute or chronic blood loss Pelvic discomfort caused by leiomyomata, either acute and severe or chronic lower abdominal or low back pressure or bladder pressure with urinary frequency not due to urinary tract infection Uterine leiomyoma(ta) of at least 2 cm size In good health. Chronic medication use is acceptable except for glucocorticoid use. Other chronic medication use may be acceptable at the discretion of the research team. Interval use of over-the-counter drugs is acceptable but must be recorded Menstrual cycles of 24 days Hemoglobin greater than 10 g/dL (for those wishing surgery); iron may be administered to improve red blood cell counts Willing and able to comply with study requirements  Significant abnormalities in the history, physical or laboratory examination Pregnancy Lactation Use of oral, injectable or inhaled glucocorticoids or megestrol within the last year Unexplained vaginal bleeding History of malignancy within the past 5 years Use of estrogen or progesterone-containing compounds, such as oral contraceptives and hormone replacement therapy, within 8 weeks of study entry, including transdermal, injectable, vaginal and oral preparations Use of agents known to induce hepatic P450 enzymes; use of imidazoles Current use of Gonadotropin-releasing hormone (GnRH) analogs or other compounds that affect menstrual cyclicity Follicle stimulating hormone (FSH) greater than 20 IU/mL


eligible ages (years): 40.0-999.0,  All  Menopause Insomnia Women 40+ years old Subject must have any of the following perimenopausal or postmenopausal signs and symptoms as defined by the Stages of Reproductive Aging Workshop (STRAW) Early Menopausal Transition (Stage -2): Variable cycle length >7 days different from normal Late Menopausal Transition (Stage -1) : > 2 skipped cycles and an interval of amenorrhea > 60 days Post Menopause (Stage +1): Amenorrhea for at least 12 months Surgical Post Menopause Hysterectomized women with one or both ovaries preserved will be eligible if FSH levels > 20 IU/L If on hormonal therapy, history of menstrual-cycle abnormalities consistent with any of 2a-2e above indicating peri-/postmenopausal status prior to initiation of hormonal therapy One or both the following insomnia symptoms for ³ 3 nights per week for at least one month prior to study enrollment Difficulty initiating sleep (³ 30 minutes)  According to M.I.N.I (Mini International Neuropsychiatric Interview), subject meets current or past for past 3 months Major Depression Dysthymia Panic disorder PTSD (Post-Traumatic Stress Disorder) According to M.I.N.I, subject has no evidence of current suicidal ideation, homicidal ideation, or psychotic symptoms at screening visit Suicide attempt in the past 5 years According to M.I.N.I, subject meets for substance use disorder diagnosis within the past 5 years Subject has current or recent use (in the past month and used > 25% of time) of hypnotic agents Subject is on an antidepressant or hormone therapy in past 2 months. (Unless they are taking currently and have had a stable dose for ≥ 2 months)


eligible ages (years): 20.0-999.0,  All  Dysmenorrhea Patients aged 20 years or older at obtaining informed consent Patients having the normal menstrual cycle (25 to 38 days) in the latest two menses before the final enrollment Patients having a total dysmenorrheal score of at least 3 points in twice of the latest menstruation before the final enrollment  Patients with ovarian chocolate cysts Patients with fibroid needed to be treated Patients with estrogen-dependent tumors and patients with cervical cancer or suspected cervical cancer Patients with undiagnosed abnormal vaginal bleeding Patients with thrombophlebitis, pulmonary embolism, cerebrovascular disease, or coronary artery disease or a history of those diseases Patients aged 35 years or older who smoke at least 15 cigarettes per day Patients with migraine accompanied by prodromata Patients with pulmonary hypertension or valvular heart disease Patients who are regularly taking nutritional products that contain St. John's Wort Patients who underwent surgical treatment for endometriosis within 2 months prior to screening


eligible ages (years): 18.0-45.0,  All  Bipolar Disorder Ages 18-45 Bipolar Disorder (BD) I or II (DSM-IV criteria) must agrees to communication between PI and Psychiatrist Healthy Control without Past or Current Major Depression, Psychotic Disorder, premenstrual syndrome or Premenstrual Dysphoric Disorder 31day menstrual cycles Minimum 6 menstrual cycles per year  Current DSM-IV Alcohol or Substance Abuse/Dependence Pregnancy Chronic Anovulation (<4 menstrual cycles/yr) Menopause (< 1menses in 1yr) Active thyroid disease Hormonal Contraception


eligible ages (years): 20.0-45.0,  All  Breast Pain Premenstrual mastalgia Age 20-45 years Reliable non-hormonal contraception  Pregnancy Breast cancer or uterine corpus cancer Unexplained menstrual disorders Serious health problems Hormonal contraception, including hormonal IUD trade name Mirena Oestrogen and/or progestin treatment Hysterectomy and/or oophorectomy or radiation therapy Artificial cardiac pacemaker/metallic prostheses


eligible ages (years): 6.0-18.0,  All  ADHD Trichotillomania DSM-IV Diagnosis of trichotillomania DSM-IV diagnosis of ADHD Has not taken stimulants or alpha-adrenergic medications for more than 2 weeks prior to entering the study  History of moderate or severe adverse event, related to MPH History of any psychotic disorder Current drug abuse, acute psychotic or affective disorder


eligible ages (years): 18.0-999.0,  All  Metrorrhagia Women age 18 or older who are initiating Depo-Provera for contraception English or Spanish-speaking Have a negative urine pregnancy test  Contraindications to either Depo-Provera or Femring (estrogen vaginal ring) Have used Depo-Provera or Mirena in the prior 6 months Have had an induced abortion, spontaneous abortion, or birth in prior 8 weeks


eligible ages (years): 18.0-48.0,  All  Premenstrual Syndrome Meets DSM-IV for PMDD by history Regular menstrual cycles that are 25 to 35 days in length during the year prior to study entry Willing to use barrier methods of birth control during the study if sexually active If engaged in psychotherapy for at least 3 months before study entry, participation will be allowed if the intensity of psychotherapy remains the same during the study Normal PAP and physical exam, including pelvic exam, within the 1 year prior to study entry  Use of oral contraceptives or other exogenous hormone preparations within the 3 months prior to study entry Suicide attempt or severe suicidal ideation within the 2 years prior to study entry History of any psychotic disorder or bipolar disorder Substance abuse, except nicotine, within the 6 months prior to study entry Use of pharmacological treatment for PMDD symptoms (e.g., antidepressants, hormones, gonadotropin-releasing hormone agonists, anxiolytics, calcium, herbal preparations, diuretics) within the 3 months prior to study entry Daily use of psychotropic or anticonvulsant medications within the 3 months prior to study entry Use of sleeping pills more than once per week Consumption of more than 50 ounces of alcohol per week Pregnant or breastfeeding Hepatic, renal, autoimmune, or chronic inflammatory disease


eligible ages (years): 18.0-45.0,  All  Premenstrual Syndrome Depression Women who are non-smokers between the ages of 18-45 years (smokers 18-34 years) Regular menstrual cycles (26-34 days in length, predictable within 7 days) for the past 6 months Determination that the antidepressant medication was initiated for the treatment of unipolar major depression, minor depression (depression, not otherwise specified), or dysthymia. Major depression and dysthymia will be evaluated through administration of the Mini-International Neuropsychiatric Interview (MINI). Minor depression will be evaluated by administration of the Structured Clinical Interview for Diagnosis-IV(SCID)10 section J.3 Use of an antidepressant for at least 3 months for treatment of a depressive disorder, with stable dose for at least 2 months. It is acceptable to be on more than one psychiatric medication as long as one of them is an antidepressant Expected continued use of the same antidepressant at the same dose for the duration of the study 30% increase of the mid-follicular phase Montgomery-Åsberg Depression Rating Scale (MADRS) score to the late-luteal phase MADRS will be required for during the tracking phase of the study and will be assessed prospectively over 1 menstrual cycle Normal pelvic exam and PAP smear in the past 12 months Normal TSH at screen if on thyroid medication, must be on a stable dose for 2 months or greater, and have a normal TSH at screen Negative serum HCG at baseline, and negative urine HCG at visits 3 and 5  Amenorrhea or irregular menstrual periods (defined as unable to predict within 7 days) during past 6 months Pregnancy or breastfeeding (serum HCG test administered at baseline study visit, and urine HCG at visits 3 and 5) Current cigarette smoking in women who are older than 34 years Presence of any of the following psychiatric and substance use disorders, based on administration of the MINI at the baseline study visit Any history of mania or hypomania suggesting bipolar disorder Any lifetime history of a psychotic disorder Depression deemed by the physician investigator to be too severe to be treated in the study Use of benzodiazepines or antipsychotic to target premenstrual symptoms Luteal-phase dose adjustment of the antidepressant. Use of a hormone releasing IUD (intrauterine device) Use of an OCP or other systemic hormonal therapies (oral, transdermal or injection preparations of androgens, estrogens, or progestins) in the past 2 months Any contraindication or previous adverse event to any OCP therapy


eligible ages (years): 18.0-50.0,  All  Contraception Signed and dated informed consent Age between 18 and 50 years (inclusive), smokers maximum age of 35 years (inclusive) at Visit 1 Otherwise healthy female subjects requesting contraception and currently using a LNG, NGM, or norethindrone/norethindrone acetate containing OC in a 21-day regimen and suffering from at least moderate pelvic pain, headache or both defined by an average of the highest 3 values of >/=35 mm on a VAS during cycle days 22-28 (35 mm VAS is the expected standard deviation of the population VAS reduction) Normal or clinically insignificant cervical smear not requiring further follow up (a cervical smear has to be taken at screening visit or a normal result has to be documented within the last 6 months before screening) Women with atypical squamous cell of undetermined significance (ASCUS) can be included if they have a negative human papilloma virus (HPV) test result. The laboratory will perform an HPV test if the Pap smear result is ASCUS Able to tolerate ibuprofen and willing to use only ibuprofen supplied by the investigator  Pregnancy or lactation (less than three cycles since delivery, abortion, or lactation before start of treatment) Body mass index (BMI) >32 kg/m2 Hypersensitivity to any of the study drug ingredients Individuals not willing to consume pork and beef products. Women may be included if they are willing to take the capsules Safety relevant laboratory values, provided by the central laboratory, outside range before start of treatment Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication (such as but not limited to duodenal ulcers, gastritis, gastrectomy or gastric resection surgery, or renal compromise) Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results Any disease or condition that may worsen under hormonal treatment Undiagnosed abnormal genital bleeding Abuse of alcohol, drugs, or medicines (eg, laxatives)


eligible ages (years): 18.0-45.0,  All  Contraception Bleeding Must be of reproductive age from 18 to 45 years Must be choosing LNG-IUC for contraception Must be English-speaking Be willing to avoid additional use of exogenous hormones, such as oral contraceptives, for the duration of the study Be willing to avoid additional use of nonsteroidal antiinflammatory drugs, such as ibuprofen or aspirin for the duration of the study Be willing to comply with the study protocol, keep the bleeding diary and comply with follow-up visits and telephone interviews as scheduled Be willing and able to provide informed consent  Known or suspected pregnancy Contraindication to estrogen use, such as presence or history of venous thromboembolism Arterial thrombosis Thrombophilia disorders, or known family history of Hypertension Migraine headaches with aura or focal neurologic involvement, or any migraine over age 35 years Recent or planned future major surgery which will result in prolonged immobilization during the study period Presence or history of severe hepatic disease or liver tumors Known or suspected estrogen-dependent neoplasm


eligible ages (years): 18.0-45.0,  All  Endometriosis Infertility Chronic Pelvic Pain Tubal Ligation A patient who meets all of the following is eligible for the study Premenopausal female 18 to 45 years of age Attending for her first diagnostic laparoscopy or for laparoscopy for tubal sterilisation Has no previous history of endometriosis diagnosis through surgery  A patient who meets any of the following is ineligible for the study Already has a surgically-confirmed diagnosis of endometriosis Aged less than18 or greater than 45 Aged 18-45 but post-menopausal


eligible ages (years): 0.0-999.0,  All  Achalasia Alacrima early age onset primary achalasia patient less than 35 years old  secondary achalasia patients


eligible ages (years): 20.0-45.0,  All  Premenstrual Syndrome Person is over the age of 20 but not older than age 45 Person is willing to participate as evidenced by signing the written informed consent form Suffers from known dominant severe symptom of breast swelling and tenderness (level 7-10 according to standard scale of PMS symptoms severity) Other severe symptoms of Premenstrual syndrome (based on WHO and ACOG criteria). This may one or more of PMS symptoms with level 7-10 according to standard scale of PMS symptoms severity At work, school, home, or in daily routine, at least one of the PMS symptoms caused reduction of productivity or inefficiency At least one of the PMS symptoms caused avoidance of or less participation in hobbies or social activities At least one of the PMS symptoms interfere with relationships with others i. Timing of PMS symptom(s): during the 14 days prior to onset of menstrual flow (rather than spotting) and up to 5 days during the menstrual flow ii. Pattern and length of PMS symptomatic period: minimum of 2 days, up to 14 days iii. For PMS diagnosis two out of last three consecutive menstrual cycles were monitored by daily monitoring of symptoms  Pregnant or lactating woman Oral contraceptives during last three months, including hormonal IUD (trade name mirena) Serious health problems Unexplained menstrual disorders Treated by hormones (estrogen and progesterone) For healthy: Irregular or abnormal test results


eligible ages (years): 18.0-40.0,  All  Contraception Healthy female subjects in need for contraception will be selected to participate in the trial Each subject must be >=18 to <=40 years of age at screening and in need for contraception Each subject must have given birth to at least one child (gestational age >=28 weeks) Each subject must have a uterus with a measured length between 6.0 and 9.0 cm (extremes included) from external os to fundus uteri  A subject must not be pregnant or suspected to be pregnant A subject must not have had an ectopic pregnancy in the past or must not have a history or presence of predisposing factors for this condition such as salpingitis, endometritis or pelvic peritonitis A subject must not have a history or presence of any malignancy A subject must not have a history or presence of premalignant disease of the uterus or cervix, including endometrial hyperplasia, or (other) sex-steroid sensitive premalignancies A subject must not have an active venous thromboembolic disorder (e.g. deep vein thrombosis, pulmonary embolism) A subject must not have a history or presence of severe hepatic disease with AST and/or ALT levels of >=3 times the upper normal limit A subject must not have congenital or acquired malformations or distortions of the uterus or cervix A subject must not have large or multiple uterine fibromyomata, or a smaller uterine fibromyoma which may interfere with the insertion of the MIUS/IUD according to the investigator A subject must not have vaginal bleeding of undiagnosed etiology A subject must not have dysmenorrhea interfering with daily activities or menorrhagia


eligible ages (years): 18.0-999.0,  All  Hypertension age 18 years or older stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure >=95 and <=115 mmHg ability to provide written informed consent  severe hypertension defined as: a mean seated cuff diastolic blood pressure >=116mmHg or a mean seated cuff systolic blood pressure >=200mmHg known or suspected secondary hypertension(ex. aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma) has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or myocardial infarction, arrhythmia within the past three months has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months Type I Diabets Mellitus, Type II Diabetes Mellitus with poor glucose control as defined by fasting glucosylated hemoglobin(HbA1c) > 8% known severe or malignant retinopathy hepatic or renal dysfunction as defined by the following laboratory parameters: AST/ALT > UNL X 2, serum creatinine > UNL X 1.5 acute or chronic inflammatory status need to treatment need to additional antihypertensive drugs during the study need to concomitant medications known to affect blood pressure during the study


eligible ages (years): 40.0-60.0,  All  Hot Flushes Menopause, Premature Obesity Vitamin D Deficiency Women in late menopausal transition or early menopause Age 40-55 BMI >25 kg/m2 Suffer from menopausal symptoms Change in previously regular cycles consisting of at least ≥2 skipped cycles and an interval of amenorrhea (≥60 days) in the last year Negative pregnancy test Vitamin D insufficiency (<30 ng/ml) Weight stability (+/ ) for 3 months  No period for >12 months Hormone use (i.e. menopausal hormone therapy, oral contraceptive, other hormonal medications) in last 3 months History of hysterectomy more than 11 months ago Abnormal screening blood tests (i.e. elevated serum calcium level, elevated creatinine) History of medical conditions where Vitamin D supplementation is not indicated (i.e. chronic renal insufficiency, elevated calcium, sarcoidosis or other granulomatous disease, lymphoma, or tuberculosis History of osteoporosis or osteoporosis on baseline DXA (expect less than 4% of screened population)84 Vitamin D deficiency (<10 ng/ml) as we felt it was unethical to withhold supplementation for 12 months in severe deficiency (according to our KPNW survey, this will <2% of population) Consuming more than 400 IU of Vitamin D supplementation daily (we felt such doses taken outside of the study design could confound results) Current smoker (within the last year) Taking medications that affect body weight


eligible ages (years): 18.0-45.0,  All  Uterine Hemorrhage Signed and dated informed consent Healthy female subjects requesting contraception Age: 18 years inclusive Successful interval insertion of History of regular cyclic menstrual periods Normal or clinically insignificant cervical smear not requiring further follow up  Pregnancy or lactation Climacteric symptoms prior to the screening visit Known or suspected clinically significant ovarian cysts, endometrial polyps, fibroids, or other genital organ pathology, that, in the opinion of the investigator, may interfere with the assessment of the bleeding profile during the study Undiagnosed abnormal genital bleeding Current or history of thrombembolic disease, or established risk factors for venous thromboembolism Current migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia, or exceptionally severe headaches Hypersensitivity to any ingredient of the investigational medicinal products or the non-investigational medicinal product Daily or frequent use of a nonsteroidal anti-inflammatory drug (NSAIDs) for any condition Not willing to use nonsteroidal anti-inflammatory drug (NSAIDs) medication as pain medication during the double blind treatment period


eligible ages (years): 18.0-40.0,  All  Healthy Middle-aged Subjects Age Range Was 18 to 31 Years Caucasian Whites Males and Females healthy middle-aged subjects  volunteers with systemic or ocular diseases


eligible ages (years): 18.0-45.0,  All  Cyclic Mastodynia Premenstrual Syndrome Females aged 18 to 45 who have signed an Informed Consent Form (ICF) at screening visit S-2 (screening visit -2) at the latest Subject has a history of cyclic mastodynia and premenstrual syndrome Stable cycle duration of 25 to 35 days during the past 6 months before screening visit S-2 At screening visit S-2 subject is reporting at least one physical premenstrual syndrome symptom rated moderate or severe (lead symptom requiring treatment) and one psychic symptom for the late luteal phase of the preceding cycle, using the Calendar of Pre-menstrual Experiences (COPE) symptom list At screening visit S-2 subject is reporting symptoms of a total score of at least 15 in the late luteal phase of the preceding cycle, using the Calendar of Pre-menstrual Experiences (COPE) symptom list In both run-in cycles Visual analog scale greater or equal 50 mm at least on one of the days of the late luteal phase Cyclic course of the mastodynia, i.e. visual analog scale in the mid follicular phase (maximum value of 5 daily recordings) is less than 75 % of the visual analog scale in the late luteal phase (maximum value of 5 daily recordings) Premenstrual syndrome sum score resulting from Calendar of Pre-menstrual Experiences (COPE) must be 20 or more in the late luteal phase (average of daily recordings documented on days -5 to -1) At least one physical premenstrual syndrome symptom must have been rated moderate or severe on at least one day of the late luteal phase, and one psychic symptom is present  Pre Menstrual Dysphoric Disorder Intake of any of the following medications before treatment start (visit S-2 up to visit V0) and within 6 months prior to visit S-2 Any treatment for mastodynia or premenstrual complaints Sexual hormones, combinations and inhibitors Pituitary hormones and their inhibitors Hypothalamic hormones Neuroleptics, antidepressants Serotonin-re-uptake-inhibitors Prolactin-inhibitors or prolactin stimulating preparations


eligible ages (years): 18.0-44.0,  All  Infertility infertile females with preserved gonadal function ages 18 years old included first oocyte donation cycle  BMI: > 28 recurrent miscarriages (3 or more) recurrent of implantation failure severe male factor important miomas > 44 years old Problems with the drugs used in the study


eligible ages (years): 45.0-55.0,  All  Perimenopausal Depression Females who are currently physically well and between 45 and 55 years of age Current DSM-IV diagnosis of depression disorder Able to give informed consent Perimenopausal as determined by symptom profile on the Stages of Reproductive Aging Workshop and gonadal hormonal profile  Known abnormalities in the hypothalamic-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event, breast pathology, undiagnosed vaginal bleeding or abnormal Pap smear results in the previous 2 years Patients with any significant unstable medical illness such as epilepsy and diabetes or known active cardiac, renal or liver disease; or the presence of illness causing immobilisation Patients receiving treatment for depression including antidepressant medications, electroconvulsive therapy (ECT) / Transcranial Magnetic Stimulation (TMS), formal psychotherapy or counselling, within the past 6 months Patients experiencing severe melancholia, neurovegetative symptoms or current suicidality necessitating acute hospitalisation or intensive psychiatric treatment Patients with psychotic symptoms or past history of severe mental illness including schizophrenia, and bipolar disorder Use of any form of estrogen, progestin or androgen as hormonal therapy, or antiandrogen including tibolone or use of phytoestrogen supplements as powder or tablet Pregnancy / Lactation Smoking cigarettes and other nicotine products illicit drug use and more than 3 standard drinks per day


eligible ages (years): 18.0-999.0,  All  Uterine Fibroids Age>18 years Premenopausal Symptomatic fibroids Fibroids accessible for focused ultrasound treatment  Desires future fertility Current pregnancy Hematocrit <30% Emergency room visit in last 3 months for fibroid symptoms History of venous thromboembolism Fibroids that are: >10cm, non-enhancing with contrast Adenomyosis Contraindications to undergoing MRI Unexplained menstrual irregularity


eligible ages (years): 20.0-40.0,  All  Endometriosis for patients with endometriosis Female patients with ovarian endometriosis, peritoneal and recto-vaginal Aged between 20 and 40 Signing of informed consent for collection and storage of biological samples  Contraindications for endometrial biopsy Failure to sign informed consent for collection and storage of biological samples


eligible ages (years): 0.0-21.0,  All  Menorrhagia Menstruating females with menorrhagia or menometrorrhagia referred to hematology or gynecology clinics at Texas Childrens Hospital. Menorrhagia is defined as regular periods with heavy menstrual bleeding with a PBAC score greater than 100; menometrorrhagia is heavy vaginal bleeding occurring at irregular intervals PBAC Score greater than 100 for 2 consecutive cycles Pelvic ultrasound that excludes pelvic pathology that can cause menorrhagia within 12 months prior to study participation Normal external genitalia examination within 6 months prior to study participation Normal thyroid stimulating hormone (TSH) in the last 6 months prior to study participation Negative urine or serum pregnancy test within 4 weeks prior to study participation  Presence of intra uterine device Presence of a diagnosed bleeding disorder based on the standard work-up including complete blood count (CBC), prothrombin time, partial thromboplastin time, fibrinogen, von Willebrand panel and platelet function analysis (PFA-100) or platelet aggregation Intake of medications with increased risk of bleeding Taking herbal products Sexually active status Body weight less than 40 kg


eligible ages (years): 18.0-35.0,  All  Copper Intrauterine Device Induced Bleeding Regularly menstruating women before CIUD insertion Age between 18 and 35 years Hormonal treatment has not been taken at least two months before the study Non steroidal anti-inflammatory drugs has not been taken 24 hours before the examination  Pregnancy The presence of pelvic pathology as ovarian cysts, pelvic endometriosis, endometrial polyps or fibrosis Present or past history of pelvic inflammatory disease Patients on hormonal treatment in the last two months before the study Patients on non steroidal anti-inflammatory drugs last 24 hours before the examination


eligible ages (years): 18.0-55.0,  All  Uterine Fibroids Women, age between 18 and 55 years Weight < 140 kg Pre or peri-menopausal Uterine size < 24 weeks Cervical cell assessment by Pap smear/Thin-prep Cytologic Test (TCT): Normal, Low Grade Squamous Intraepithelial Lesion (SIL), Low risk Human Papillomavirus (HPV) or Atypical Squamous Cells of Uncertain Significance (ASCUS) subtypes of cervical tissue Fibroids selected for treatment meeting the following Total planned ablation volume of all fibroids should not exceed 250 ml, and No more than 5 fibroids should be planned for ablation, and Dominant fibroid (diameter) is greater than or equal to 3 cm, and  Other pelvic disease (Other mass, endometriosis, ovarian tumor, acute pelvic disease, significant adenomyosis) Desire for future pregnancy Significant systemic disease, even if controlled Positive pregnancy test Hematocrit < 25% Extensive scarring along anterior lower abdominal wall (> 50% of area) Surgical clips in the direct path of the HIFU beam MRI contraindicated MRI contrast agent contraindicated Fibroids not quantifiable on MRI (e.g. multi-fibroid cases where volume measurements are not feasible)


eligible ages (years): 20.0-45.0,  All  Adenomyosis Women have dysmenorrhoea and/or chronic pelvic pain secondary to adenomyosis Planning for birth spacing for at least 2 years Patient aged between 20-45 years old Ultrasonographic and Doppler examination suggestive of adenomyosis Living in a nearby area to make follow-up reasonably possible  Pregnancy Evidence of defective coagulation History or evidence of malignancy Hyperplasia in the endometrial biopsy Incidental adnexal abnormality on ultrasound Contraindications to COCs Absolute contraindication of LNG-IUS insertion Previous endometrial ablation or resection Uninvestigated postcoital bleeding Untreated abnormal cervical cytology


eligible ages (years): 21.0-999.0,  All  Uterine Fibroids Premenopausal (at least 1 menstrual period in last 3 months) Age >21years Fibroids are associated with heavy bleeding, pelvic pressure or discomfort, urinary or bowel symptoms, or dyspareunia Desires surgical management of fibroids Uterus ≤16 weeks in size All fibroids ≤ 10cm in maximum diameter by ultrasound or MRI assessment within the last year Total number of fibroids ≤6 by ultrasound or MRI assessment within the last year. (For this study "Fibroids" will be leiomyomas > 2cm) Had a Pap smear within the last 3 years with appropriate follow-up and treatment for cellular abnormalities Endometrial biopsy indicates no hyperplasia or cancer (biopsy only required if age >45 years and has anovulatory heavy bleeding) Able to tolerate laparoscopic surgery  Planned treatment for infertility Pedunculated fibroid with thin stalk (total stalk length is <25% maximum diameter of fibroid) Intracavitary (FIGO Type 0) fibroid Symptomatic fibroids are only FIGO Type 1 (submucosal with ≥ 50% intracavitary) Planned concomitant surgical procedure in addition to treatment of uterine fibroids Use of Essure or any other metallic, implantable device within pelvis Pregnancy Pelvic infection with the last 3 months History of pelvic malignancy and/or pelvic radiation Known or high suspicion for dense pelvic adhesions


eligible ages (years): 18.0-60.0,  All  Low Back Pain Symptom of low back pain during last 4 weeks Low back pain history for more than 3 months  Have lower limbs radiating pain beyond knee joints Spinal tumorous or infectious disease, fracture, ankylosing spondylitis, cauda equina syndrome or other severe spinal diseases Spinal surgical history Severe heart, lung, liver, kidney disease or high blood pressure With cardiac pacemaker Coagulopathy or thrombosis Have ESW therapy or pharmaceutical treatment for low back pain during last 1 months Mental illnesses or none cooperation Pregnancy


eligible ages (years): 18.0-999.0,  All  Uterine Leiomyomas Fibroids Uterine Fibroids Myomas Able and willing to give consent Age 18 or older Presence of known uterine leiomyoma  Suspected malignancy


eligible ages (years): 18.0-35.0,  All  Endometriosis Age 18-35 years of age. Written and signed informed consent by the patient to participate in the study. Patients with regular menses, both ovaries, serum TSH within normal range, body mass index (BMI) <30 kg/m2 with normal sperm analysis of the husband  Patients with previous endocrine disorders. Cases in which the cause for infertility was other than endometriosis (except for patients with tubal obstruction, in the control group) Patient with previous surgery for endometriosis


eligible ages (years): 18.0-38.0,  All  Endometriosis aged18-38 years clinically diagnosed with endometriosis (Stage I-IV) patient is seeking pain relief from symptoms of endometriosis/ pelvic pain/ dyspareunia/ dysmenorrhea  pregnancy or current breastfeeding use of hormonal suppression for symptom control (OCP, progestins, GnRHa) within past 3 months surgical treatment for endometriosis within last 3 months history of renal disease, liver dysfunction, myopathies in the past baseline AST, ALT or creatinine levels that are more than 1.5 times the normal limits current use of medications that may interact with statins (erythromycin, gemfibrosil, antifungals, antiretroviral, other cholesterol lowering drug etc)


eligible ages (years): 20.0-45.0,  All  Adenomyosis Infertility Dysmenorrhea Premenopausal women aged 20-45 years having been diagnosed with adenomyosis earlier and have no other pathology of the uterus, regardless of clinical symptoms  Postmenopausal women Pregnant women Gynaecological cancer GnRH analog therapy or systemic hormone therapy in the last three months prior to hysterectomy Endometriosis Uterine fibroids


eligible ages (years): 25.0-50.0,  All  Adenomyosis Premenopausal women aged 30 years old scheduled for vaginal, abdominal or laparoscopic total hysterectomy one or more of the following clinical symptoms: bleeding disorders (menorrhagia, irregular bleeding, hypermenorrhoea), chronic pelvic pain, dysmenorrhoea, or dyspareunia junction zone definable  postmenopausal women pregnancy gynecological cancer GnRH analog therapy or systemic hormone therapy in the last three months prior to hysterectomy junctional zone not identifiable


eligible ages (years): 38.0-52.0,  All  Adenomyosis females complaining of pelvic congestion: dysmenorrhea, dyspareunia, chronic pelvic pain, menorrhagia, metrorrhagia  refusal of the patient to get enrolled in the study


eligible ages (years): 18.0-37.0,  All  Deep Endometriosis Stage III Deep Endometriosis Stage IV female patient between 18 and 38 years endometriosis stage III or IV in the AFSr classification laparoscopy included deep endometriosis procedures (adhesiolysis, ureterolysis, cystectomy, resection of bowel, urinary or deep peritoneal endometriosis) written informed consent  previous adnexectomy or adnexectomy during surgery


eligible ages (years): 18.0-90.0,  All  Constipation diagnosis of constipation according to Roma III complete bowel movements per week <3 total bowel movements per week <6 written informed consent  report of loose (mushy) or watery stool in the absence of laxative use ongoing artificial nutrition lactose intolerance chronic inflammatory bowel disease previous abdominal surgery use of anti-cholinergics use of antibiotics in the 6 weeks before baseline visit Radio chemotherapy Cognitive decline (Mini Mental State Examination <27)


eligible ages (years): 21.0-999.0,  All  Leiomyoma Uterine Fibroids ≥21 years old Premenopausal (at least one menses in last 3 months) Symptomatic fibroids (fibroids visualized on ultrasound or MRI and heavy uterine bleeding, pelvic pressure or discomfort, urinary or bowel abnormalities, dyspareunia) Fibroids that are ≤4 in total number or Fibroids that are ≤7 in total number if all fibroids are less than 4cm (40 mm) each Fibroids that are ≤7cm in maximum diameter, on screening imaging, if ≤4 fibroids in total number(fibroid is defined as any mass with radiographic characteristics of fibroid >2cm) Up to date in Pap smear screening and surveillance Endometrial biopsy (required if age>45 years with irregular bleeding) does not indicate premalignant or malignant cells Agree to use non-hormonal barrier method of contraception during study period if at risk for pregnancy Has primary care provider or gynecologist Agrees not to start new medications/treatments for fibroids during the study  Fibroids treated by surgery, radiologic procedure, or GnRH agonist or antagonist in the last 3 months Any submucosal fibroid ≥2cm that is >50% in uterine cavity (FIGO Type 0 or Type 1 fibroids) amenable to hysteroscopic resection Use of exogenous estrogen and/or progestin in the last month. (for 3 month long-acting depoprovera injection, no use in last 3 months) Pregnant, lactating, or planning to become pregnant in the next 6 months Hematocrit <27% or visit to emergency room or hospitalization for fibroid symptoms in the last 3 months (cannot be safely randomized to a placebo) History of osteopenia or osteoporosis History of hyperlipidemia Current liver or kidney disease Unable or unwilling to attend 4 study visits Pelvic imaging concerning for gynecologic cancer or cancer of the genitourinary or gastrointestinal system


eligible ages (years): 18.0-38.0,  All  Endometriosis Patients over 18 years Patients operated by laparoscopy for endometriosis in our department between 2006 and 2014  Patients under 18 years


eligible ages (years): 18.0-999.0,  All  Endometriosis Quality of Life Pain Sexuality Anxiety Depression Infertility female >18 years fluent German Cases: diagnosis of endometriosis Control 1: no endometriosis, no chronic pain Control 2: no endometriosis, chronic abdominal/pelvic pain  male <18years not fluent in German


eligible ages (years): 18.0-100.0,  All  Uterine Fibroid Able to give informed consent A type 3 uterine fibroid Sufficient physical condition to undergo deep sedation Waist circumference that allows positioning on the HIFU table top inside the MR bore  Contra-indication for MRI scanning according to the hospital guidelines Contra-indication to injection of gadolinium-based contrast agent, including known prior allergic reaction to any contrast agent, and renal failure (GFR <30 mL/min/1.73 m2) Surgical clips or considerable scar tissue in the HIFU beam path A total of more than ten fibroids Post or peri-menopausal status Fibroid size >10 cm in diameter Patient has an active pelvic infection Patient has an undiagnosed pelvic mass outside the uterus Patient who is not able to tolerate the required stationary prone position during treatment


A 56-year old Caucasian female complains of being markedly more sensitive to the cold than most people. She also gets tired easily, has decreased appetite, and has recently tried home remedies for her constipation. Physical examination reveals hyporeflexia with delayed relaxation of knee and ankle reflexes, and very dry skin. She moves and talks slowly.

eligible ages (years): 0.0-17.0,  All  Guillain-Barre Syndrome ENTRY --Disease Characteristics-- Guillain-Barre syndrome (GBS): Progressive weakness of two or more limbs; Absence or reduced tendon reflexes; No atypical symptoms of GBS (e.g., Miller-Fisher variant); No pure sensory neuropathy; No prior history of GBS Disability at least grade 3 according to Guillain-Barre Study Group grading scale (unable to walk 5 meters without assistance); Must not have improvement of one or more disability grades prior to randomization in this study No paresthesias, numbness, or weakness that began more than 14 days before randomization in this study No CNS involvement --Prior/Concurrent Therapy-- Biologic therapy: No prior treatment with plasmapheresis or infusion of human immunoglobulin (IVIg) Endocrine therapy: No concurrent corticosteroids or other immunosuppressants (except for concurrent medical conditions, e.g., asthma) Radiotherapy: Not specified


eligible ages (years): 18.0-45.0,  All  Bacterial Infections Group B Streptococcus This information currently is not available


eligible ages (years): 18.0-999.0,  All  Hypothyroidism Male or female subjects >18 years of age Primary hypothyroidism ≥6 months duration arising from autoimmune hypothyroidism, thyroidectomy or radioiodine treatment Thyroxine dose ≥100 mcg/day No change in thyroxine dose in past 2 months Serum TSH of 0.1-4.8 mU/L Adequate contraceptive measures for women of childbearing age  Major systemic illness affecting quality of life or likely to affect participation in the study Treatment with T3 currently or in past 2 months History of thyroid cancer requiring suppression of TSH secretion by thyroxine Ischaemic heart disease – previous myocardial infarction, angina or coronary artery revascularisation Renal failure: serum creatinine >135 micromol/L Known liver disease with alkaline phosphatase or ALT >2x upper limit of reference range Bony fracture in past 3 months or Paget’s disease of bone Secondary (central) hypothyroidism or hypopituitarism


eligible ages (years): 5.0-17.0,  All  Influenza Healthy children enrolled in the target schools Written informed consent obtained from the child's parent(s) if they agree to participate  History of severe hypersensitivity (anaphylactic response) to egg products or previous FluMist FluMist is licensed exclusively for use in healthy individuals age 5-49 years. Therefore children for whom annual receipt of inactivated influenza vaccine for specific medical condition(s) is recommended will not be eligible. These conditions Asthma, other chronic pulmonary diseases, kidney disease, metabolic disease, heart disease, or hemoglobinopathy Immunosuppression of child Severe immunosuppression of a household member Pregnancy Past history of Guillian-Barre Syndrome Aspirin therapy within 1 month prior to FluMist or the anticipated use of aspirin containing products for one month after FluMist administration Administration of any inactivated vaccine within 2 weeks or any live vaccine within 4 weeks prior to receipt of FluMist Received anti-influenza medication in the past 48 hours


eligible ages (years): 8.0-17.0,  All  Hypothyroidism Patients should have clinical and biochemical evidence of hypothyroidism, T4 less than 5.0 ng /dl , fT4 less than 1.0 mcg/dl and TSH of more than 10. Patients with prolonged hypothyroidism should have growth failure and delayed bone age of at least 2 SD from the mean. Patients with short term hypothyroidism should have normal growth velocity and bone age Females 8 to 16 years old Males 9 to 17 years old Patients without any chronic medical conditions Availability of a parent or guardian to attend study visits with the patient and to be actively involved in the patient treatment plan Give written informed consent prior to any study specific screening procedure with the understanding that the patient has the right to withdraw from the study at any time without penalty  Taking medications that affect their growth. (eg. Systemic corticosteroids, anabolic steroids) Experiencing other health problems/conditions that affect their growth rate such as growth hormone deficiency, Cushing Syndrome, rickets, and chronic diseases Patients with any condition that is a contraindication for GH therapy would conditions such as an active tumor, impaired glucose tolerance, neurofibromatosis (worsening of neurofibromatosis), and hypertrophy of tonsils and adenoids with sleep apnea. Contraindications for patients for GNRHa therapy would a severe systemic reaction to GNRHa which is rare, osteopenia, and osteoporosis, because delaying puberty will worsen the condition Moving to a location that the patient will not be able to be followed by a pediatric endocrinologist Patient is not willing to continue with the study. -


eligible ages (years): 0.0-0.192,  All  Congenital Chylothorax Infants with congenital chylothorax requiring thorax drain


eligible ages (years): 0.0-999.0,  All  Hypothyroidism Defined group of women who tested positive for post partum thyroiditis in 1985 Control group randomly picked from those who tested negative


eligible ages (years): 18.0-64.0,  All  Influenza Healthy Adults  Previous vaccination with an influenza Vaccine containing the H5N1 strain History of clinically significant medical conditions History of Guillian-Barre Syndrome or active Neurological disease


eligible ages (years): 18.0-999.0,  All  Advanced Cancer Patient with drowsiness/sedation caused by opiate for > 3 days and its intensity more or equal to 3/10 (0 to 10 scale; 0 = no sedation, 10=worst possible sedation) Patient receiving a regular dose of a strong opioid for the treatment of cancer pain, and no dose changes or dose change within 50% for at least 48 hours.Regular administration, defined as short acting opioids oral or parenteral every 4 hours around clock, slow release oral opioids every 12 hs or 24 hs, or transdermal opioids every 72 hours. Strong opioids morphine, hydromorphone, methadone, fentanyl, and oxycodone Patient with relatively intact cognition defined by the Mini Mental State Examination according to age and educational level. A score of 24 or above is usually considered normal Patient willing to engage in follow up visit with a nurse by phone on day 2-7 (each day), 11 and 15 of the study and to return for follow up visit on day 8 of treatment. If patient is unable to come to clinic, assessment will be performed through telephone Sexually active females at risk of being pregnant with a negative urine pregnancy test Written consent form signed Patients are 18 years or older Concurrent radiation treatment (defined as 10 or less fractions for a palliative indication) is allowed Concurrent chemotherapy is allowed, if the first two cycles have been well tolerated (defined as no grade 3 or 4 non-hematological toxicity)  Major contraindication to donepezil i.e. hypersensitivity to donepezil or piperidine derivatives Patients in whom a major change in opiate dose, analgesia requirements, anesthetic procedures or general anesthetic is expected over the next seven days Treatment with anti-cholinergic agents (i.e., glycopyrrolate) Patients taking Methylphenidate Patients with tube feeding (due to difficulty of accurate assessing some of the symptoms such as appetite and anorexia) History of ongoing arrhythmia causing a rhythm other than a sinus rhythm


eligible ages (years): 18.0-90.0,  All  Dry Eye Syndromes Signed and dated informed consent Male or female aged from 18 to 90 years old Known treated bilateral dry eye Dry eye syndrome confirmed by ocular examination with a fluorescein and/or lissamine green staining, BUT and Schirmer, performed within the last 12 months before Visit, for both eyes Bilateral symptomatology suggestive of dry eye defined by: at least one of the following ocular symptoms suggestive of dry eye (burning, stinging, dryness feeling, sandy and/or gritty sensation, light sensitivity, reflex tearing, ocular fatigue) and Questioning on patient’s feeling (score >=3) Fulfilling the following of dry eye syndrome in both eyes defined by: Keratoconjunctivitis defined by a lissamine green score ≥ 4 (Van Bijsterveld score) and Schirmer test <= 10 mm in 5 min or BUT < 10 s  severe dry eye symptom eyelid dysfunction severe progressive rosacea any relevant ocular anomaly interfering with ocular surface best corrected far visual acuity <= 1/10 history of ocular allergy traumatism, infection, inflammation within last 3 months ocular surgery and laser within the last 3 months lasik, laser, PKR within the last 12 months contact lenses


eligible ages (years): 18.0-75.0,  All  Secondary Hypothyroidism Hypopituitarism Hyperlipidemias hypopituitarism of at least 3 axes (TSH plus gonadotropin, somatotropin, corticotropin or ADH deficiency) termination of surgical or radiation treatment of pituitary tumors at least six month before study entry BMI of 20 9 kg/m2 non-smoking status  history of cardiovascular or pulmonary diseases current thyroxin dosage > 1.6 µg/kg bw pregnancy epilepsy cerebrovascular diseases nodular goiter


eligible ages (years): 20.0-999.0,  All  Neoplasms, Gastrointestinal Tract Specific Information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the investigational product that may impact subject is provided in the Investigator's Brochure (IB) Pilot Part Subjects eligible for enrollment in the Pilot Part of the study must meet all of the following Signed informed consent Male or female; ≥ 20 years (at the time of giving consent) Any histologically or cytologically confirmed gastric carcinoma independent of tumor ErbB2 status Subjects who have received one prior regimen for gastric carcinoma and developed disease progression or recurrence. The regimen must have contained 5-fluoropyrimidine and/or cisplatin Left ventricular ejection fraction (LVEF) within institutional range of normal as measured by echocardiogram (ECHO). Multigated acquisition (MUGA) scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive (LVEF of ≥50% required if normal range of LVEF is not provided by institution) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 Able to swallow and retain oral medication Women and men with potential to have children must be willing to practice acceptable methods of birth control during the study  Subjects meeting any of the following must not be enrolled in the study Pregnant or lactating female at anytime during the study Planned concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatment Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities greater than grade 2) Peripheral neuropathy of Grade 2 or greater Malabsorption syndrome, disease significantly affecting gastrointestinal function. Subjects with ulcerative colitis and Crohn's disease are also excluded History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety Life threatening infection Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent


eligible ages (years): 0.0-999.0,  All  Congenital Hypothyroidism Patients with congenital hypothyroidism due to thyroglobulin defective synthesis  Patients with another disease


eligible ages (years): 18.0-999.0,  All  Hypothyroidism Newly diagnosed hypothyroidism with tsh over 40 mU/L, etiology chronic autoimmune thyroiditis Healthy controls matched regarding sex, age and body mass index  Pregnancy, breastfeeding


eligible ages (years): 23.0-73.0,  All  Iron Deficiency Anemia Subclinical Hypothyroidism Clinical diagnosis and laboratory confirmation of iron deficiency anemia and subclinical hypothyroidism Must be able to swallow tablets  Multifactorial anemia or anemia due to other reasons Iron deficiency anemia requiring urgent intervention cardiac ischemia, severe anemia, GI or GU losses due to malignancy and or acute/subacute big loses by respiratory, Gİ, GU, etc. system Prior thyroid disorder and/or treatment history Presence of any other co-morbid disease like renal insufficiency/ failure, coronary heart disease, hypertension, diabetes mellitus, any endocrine system disease other than subclinical hypothyroidism


eligible ages (years): 20.0-90.0,  All  Thyroid Nodule age between 20 to 90 years old Benign nodular goiter diagnosed with thyroid echo and fine-needle aspiration cytology  Age younger than 20 or older than 90 years old Pregnancy Allergy to eltroxin Taking other drugs which will have drug interaction with eltroxin patients with cardiovascular disease, hypertension, gastrointestinal disease


eligible ages (years): 0.0-0.077,  All  Hypothyroxinemia Birth weight: less than 1500g Gestation: 22 weeks 0 day ≤ Serum free thyroxine level lower than 0.8 ng/dl Serum thyrotropin lower than 10 μU/ml Age of between 2 and 4 weeks after birth Informed consent  any known thyroid disease in mother


eligible ages (years): 2.0-6.0,  All  Gram Positive Infection Concurrent Antibiotic Treatment Written parental (or appropriate legal representative) informed consent prior to any study-related procedure not part of normal medical care Male or female between the ages of 2 and 6 years old, inclusive Able to comply with the protocol for the duration of the study Clinically stable with no evidence of hemodynamic instability (defined as a requirement for pharmacological intervention to manage blood pressure) in the 72 hour window prior to enrollment, and no history or evidence of renal or hepatic compromise Suspected or diagnosed Gram-positive infection for which the subject is receiving standard antibiotic therapy A calculated creatinine clearance rate (CLcr) ≥ 80 ml/min/1.73m2 as determined by the Schwartz equation at baseline Creatine phosphokinase (CPK) levels less than 2X ULN (upper limit of normal) at baseline Presence of two patent intravenous lines (or comparable means of venous access) prior to dosing on Study Day 1  Investigational drug use (including daptomycin) or participation in any experimental procedure in the 30 days preceding study entry Known allergy/ hypersensitivity to daptomycin History of clinically significant cardiovascular, renal, hepatic, pulmonary (well-controlled asthma is acceptable), gastrointestinal, endocrine, hematologic, autoimmune disease or primary immune deficiency Pneumonia as sole Gram-positive infection being treated with standard antibiotics Subjects with clinically significant abnormal laboratory test results [including electrocardiograms (ECGs)], as determined by Investigator Administration of rifampin within 7 days of study drug administration Body mass index (BMI) that is outside of the 5th to 95th percentile Subjects in whom collection of the required blood volume would put them at risk of hemodynamic disturbance (at the discretion of Investigator) History of or current clinically significant (at the discretion of the Investigator) muscular disease, nervous system or seizure disorder Administration of intramuscular injection between baseline and study drug administration or expected intramuscular injection within 24 hours following dosing


eligible ages (years): 18.0-48.0,  All  Hypothyroidism Premenopausal women with overt primary hypothyroidism (reduced T4 concentration accompanied by increased TSH concentration at the time of initial diagnosis) who did not receive thyroid hormones  Peri and postmenopause Pregnancy Major comorbidity Use of drugs that affect metabolism or bioavailability of thyroid hormones preparations


eligible ages (years): 17.0-44.0,  All  Hypothyroidism TSH value >98th centile in early pregnancy  Women with known hypothyroidism


eligible ages (years): 18.0-80.0,  All  Schizophrenia Schizoaffective Disorder Weight Gain non-diabetic schizophrenic or schizoaffective currently prescribed olanzapine or ziprasidone 80 y.o  <18 or >80 years of age diabetic not schizophrenic or schizoaffective not currently prescribed olanzapine or ziprasidone


eligible ages (years): 18.0-80.0,  All  Depression Age 18 Written informed consent Current MDD according to the fourth version of the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV) Recently started to receive or about to start receiving treatment for MDD Quick Inventory of Depressive Symptomatology Clinician-Rated (QIDS-C) and QIDS-IVR scores equal or greater than 10 at baseline visit  Subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician. These patients will be immediately referred to appropriate clinical treatment History or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months History or current diagnosis of dementia Diagnosis or history of hypothyroidism


eligible ages (years): 18.0-70.0,  All  Arthroplasty, Replacement, Knee Scheduled for total knee replacement or revision of total knee replacement Agree to have a regional technique including neuraxial analgesia for post-operative analgesia Be 18 to 70 years old Classified as ASA score I-III  Allergic to morphine Allergic to local anesthetics Been on opioids for more than 4 weeks Not willing to be randomized On anticoagulation medications that prevent placement of epidural Sensitive to effects of neuraxial opioids BMI>35 Severe COPD Obstructive sleep apnea (OSA, see below). Each patient will be asked the questions below to determine their risk for OSA (STOP questionnaire). Patients who answer yes to 3 or more of the major of the STOP questionnaire and have one of the minor will be excluded from the study STOP Questionnaire for OSA


eligible ages (years): 4.0-18.0,  All  Chronic Constipation Less than 2 per week defecation Fecal incontinence Retentive behavior Pain at defecation and Hard stools  Medication use (calcium, antacid, diuretic and hematinic) Organic causes (spina bifid, hypothyroidism, hirschusprung disease, developmental delay neuropsychomotor, kidney disease and metabolic diseases)


eligible ages (years): 60.0-95.0,  All  Subclinical Hypothyroidism TSH between 4 and 10 mUI/L inclusive  Known and treatment of thyroideal disease Arrythmia Anticoagulant treatment Dementia Disease leading to dementia (acv, LIVER....)


eligible ages (years): 18.0-65.0,  All  Fibromyalgia Female volunteers who have been diagnosed with fibromyalgia by a rheumatologist Overall body pain average score ≥ 4 Age range: 18 to 65 years old You must be on stable doses of anyone of these fibromyalgia-related medications for at least 4 weeks: cyclobenzaprine, tramadol, gabapentin, pregabalin, amitriptyline, nortriptyline, trazodone, sertraline, fluoxetine, paxil, remeron, venlafaxine and duloxetine Willingness to restrict any change (add or switch or change in the dose) of any fibromyalgia-related medication for 12 weeks  Volunteers who have long-standing history of diabetes (> 2 years), or have been diagnosed with any type of peripheral neuropathy Have a prior history of myocardial infarction (heart attack) or unstable angina or other heart arrhythmias Have been diagnosed with multiple sclerosis or any other demyelinating disorder Have planned to undergo an elective surgery over the next 12 weeks Have other major rheumatic conditions (i.e. rheumatoid arthritis, systemic lupus erythematosus, scleroderma and other connective tissue disease) Are currently pregnant or actively trying to become pregnant


eligible ages (years): 12.0-65.0,  All  Vitiligo Any Vitiligo patient (age 12 years and above) with non-segmental Vitiligo Body surface area (BSA) involvement ≥ 3%  Unable to consent Any topical, systemic or phototherapy for Vitiligo in the previous 2 months Pregnancy, breast feeding Liver or kidney disease Epilepsy Bleeding disorder or anticoagulant treatment


eligible ages (years): 18.0-999.0,  All  Anemia years or older Diagnosis of low or intermediate-1 risk Myelodysplastic (MDS) with any chromosome karyotype except del 5q[31] Anemia that requires red blood cell transfusions Resistant to erythropoiesis stimulating agents (ESAs) or blood erythropoietin level > 500 mU/mL Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2 Must agree to follow pregnancy precautions as required by the protocol Must agree to receive counseling related to teratogenic and other risks of lenalidomide Must agree not to donate blood or semen Must be willing to consent to two or more bone marrow aspirate procedures to be completed during study  Subjects previously receiving immunomodulating or immunosuppressive agents, or epigenetic or deoxyribonucleic acid (DNA) modulation agents Allergic reaction to thalidomide Renal insufficiency creatinine clearance (CrC1)<40 mL/min by Cockcroft-Gault method) Prior history of cancer, other than MDS, unless the subject has been free of the disease for ≥ 5 years. (Basal cell carcinoma of the skin, carcinoma in situ of the cervix, or stage Tumor (T) 1a or T1b prostate cancer is allowed) Absolute neutrophil count (ANC) < 500/uL Platelets < 50,000/uL Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3X upper limit of normal Uncontrolled hyperthyroidism or hypothyroidism Significant neuropathy Prior stem cell transplantation


eligible ages (years): 18.0-999.0,  All  Neuropathy Men and women, ages of 18 or greater Documented evidence of HIV-1 infection Documented diagnosis of HIV-associated Distal Symmetrical Polyneuropathy (DSP) with subjective sensory symptom of pain Pain starts in the feet  Subject has untreated vitamin B12 deficiency (serum B12 level <200 pg/ml) or if treated B12 deficiency -treatment is less than 6 months of B12 supplementation (injection or intranasal B12) prior to screening Diabetes mellitus requiring regular medical treatment (other than diet and exercise) or HbA1C >6.9 Subjects with peripheral neuropathic pain that is not associated with HIV infection; including subjects with conditions such as: Post Herpetic Neuralgia (PHN), Diabetic Peripheral Neuropathy (DPN), familial neuropathies; compression related neuropathy, radicular pain, other infection related neuropathies (eg, leprosy); neuropathy related to: metabolic abnormalities; nutritional factors; vascular insults; inflammation; autoimmune disease; and malignancy


eligible ages (years): 21.0-85.0,  All  Cerebral Stroke Ischemic or hemorrhagic stroke greater than 3 months prior Residual hemiparetic gait with observable asymmetry in the gait pattern Women or men aged 21 to 85 years Completed all conventional physical therapy Adequate language and neurocognitive function to participate in training, testing, and to give informed consent Minimal ankle flexion in either direction (dorsi or plantar-)  MMSE score < 23 (9th grade education or more) or MMSE score < 17 (8th grade education or less) CES-D score > 16 Clinical history of orthopedic, chronic pain or severe neuromuscular disorders restricting participation in a short term ankle movement training paradigm Severe or global receptive aphasia which confounds reliable testing and training Women of child-bearing potential, if there is any self-reported chance that they may be pregnant


eligible ages (years): 65.0-999.0,  All  Acute Myeloid Leukemia Diagnosis of one of the following Newly diagnosed de novo acute myeloid leukemia (AML) AML secondary to myelodysplastic syndromes (MDS) AML secondary to exposure to leukemogenic therapy or agents with primary malignancy in remission for at least 2 years Bone marrow blasts >30% Age ≥ 65 years Easter Cooperative Oncology Group (ECOG) 0-2  Previous cytotoxic or biologic treatment for AML (except hydroxyurea) Previous treatment with azacitidine, decitabine or cytarabine Prior use of targeted therapy agents (e.g., FLT3 inhibitors, other kinase inhibitors) AML French American British subtype (FAB M3) AML associated with inv(16), t(8;21), t(16;16), t(15:17), or t(9;22) karyotypes Prior bone marrow or stem cell transplantation Candidate for allogeneic bone marrow or stem cell transplant Diagnosis of malignant disease within the previous 12 months (excluding base cell carcinoma, "in-situ" carcinoma of the cervix or breast or other local malignancy excised or irradiated with a high probability of cure) Malignant hepatic tumors Uncontrolled systemic infection